section name header

Pronunciation

KWI-nine

Classifications

Therapeutic Classification: antimalarials

Indications

REMS


Action

  • Disrupts metabolism of the erythrocytic phase of Plasmodium falciparum.
  • Increases the refractory period of skeletal muscle, increases the distribution of calcium within muscle fibers, decreases the excitability of motor end-plate regions, resulting in decreased response to repetitive nerve stimulation and acetylcholine.
Therapeutic effects:
  • Death of P. falciparum.

Pharmacokinetics

Absorption: Rapidly and almost completely (80%) absorbed following oral administration.

Distribution: Varies with condition and patient; does not enter CSF well. Crosses the placenta and enters breast milk.

Protein Binding: >90% in patients with cerebral malaria, pregnant women, and children; 85–90% in patients with uncomplicated malaria; 70% in healthy adults.

Metabolism/Excretion: >80% metabolized by the liver; metabolites have less activity than quinine; metabolites excreted in urine. 20% excreted unchanged in urine. Excretion in acidic urine.

Half-Life: 11 hr ( in patients with malaria).

Time/Action Profile

(antimalarial blood levels)

ROUTEONSETPEAKDURATION
POunknown3.2–5.9 hr8 hr



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Qualaquin

Code

NDC Code